Antev: Phase 3 ready, Teverelix, a long acting injectable peptide GnRH antagonist. Lead indication for prostate cancer, followed by benign prostatic hyperplasia (BPH), acute urinary retention (AUR), uterine fibroids and endometriosis. Over 450 subjects have been dosed over 850 times to date with no serious adverse reactions and good local tolerance.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Listing
Private
Website:
Address:
2nd Floor
106 New Bond Street
London, W1S 1DN
United Kingdom

Company Participants at Boston Private Company Showcase

  • Ajmal Rahman, Chief Executive Officer

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.